Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Among them, only one had hypophosphatemia and the other serum phosphorus levels at the lower limit, both with FGF23, αKlotho, 25OHD3 and PTH within the reference range.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Neurofibromatosis type I (NF1) and bone involvement in a pediatric setting: insights from FGF23 levels

Study design awaiting verification · Italian Journal of Pediatrics · 2025

Original publication title

Neurofibromatosis type I (NF1) and bone involvement in a pediatric setting: insights from FGF23 levels

Giulia Rodari; Valeria Citterio; Masami Ikehata; Deborah Mattinzoli; Giulietta Scuvera; Federico Grilli; Eriselda Profka; Federico Giacchetti; Valentina Collini; Alessandro Risio; Claudia Cesaretti; Federica Natacci; Carlo Alfieri; Giovanna Mantovani; Claudia Giavoli

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In conclusion, this represents the first study assessing FGF23 levels in NF1 children and its possible relationship with decreased bone mineral density. Contrarily to previous observations, no significant differences were found between NF1 patients and controls regarding FGF23 and αKlotho levels. Additionally, there was no clear association between FGF23 and bone involvement, thus suggesting that this phenomenon is not FGF23-driven or FGF23 derangements might occur later in life. Further research is needed to understand the multifactorial mechanisms and determine optimal intervention strategies.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Neurofibromatosis type I (NF1) is an autosomal dominant disorder characterized by extremely different phenotypes, sometimes including reduced bone mass. The underlying cause of bone impairment in these patients remains poorly understood, especially in children. Previous studies in mice and single reports in NF1 patients with osteomalacia have shown elevated serum FGF23 levels. The aim of this study was to explore for the first time these results in NF1 pediatric patients to eventually provide biological insight into bone involvement in NF1.

Source: Background

Abstract: What methods does the paper describe?

This is an observational, cross-sectional, single-centre study evaluating FGF23/αKlotho levels, as well as other markers of bone metabolism and densitometric parameters in 31 children affected by NF1 and comparing them to 21 age: and sex-matched controls.

Source: Methods

Abstract: Results

We enrolled 31 patients with NF1(M/F 13/18; 11.7 ± 2.9 years). After correction for bone age, BMAD Z-score was < -2SDS in 5/31 patients (16.1%). No difference was found between FGF23 and αKlotho between NF1 patients and controls. No association was found between auxological, biochemical, genetic and radiological parameters and FGF23 values.

Source: Results

Abstract: Conclusion

In conclusion, this represents the first study assessing FGF23 levels in NF1 children and its possible relationship with decreased bone mineral density. Contrarily to previous observations, no significant differences were found between NF1 patients and controls regarding FGF23 and αKlotho levels. Additionally, there was no clear association between FGF23 and bone involvement, thus suggesting that this phenomenon is not FGF23-driven or FGF23 derangements might occur later in life. Further research is needed to understand the multifactorial mechanisms and determine optimal intervention strategies.

Source: Conclusion
Authors’ abstract

Background

Neurofibromatosis type I (NF1) is an autosomal dominant disorder characterized by extremely different phenotypes, sometimes including reduced bone mass. The underlying cause of bone impairment in these patients remains poorly understood, especially in children. Previous studies in mice and single reports in NF1 patients with osteomalacia have shown elevated serum FGF23 levels. The aim of this study was to explore for the first time these results in NF1 pediatric patients to eventually provide biological insight into bone involvement in NF1.

Methods

This is an observational, cross-sectional, single-centre study evaluating FGF23/αKlotho levels, as well as other markers of bone metabolism and densitometric parameters in 31 children affected by NF1 and comparing them to 21 age: and sex-matched controls.

Results

We enrolled 31 patients with NF1(M/F 13/18; 11.7 ± 2.9 years). After correction for bone age, BMAD Z-score was < -2SDS in 5/31 patients (16.1%). No difference was found between FGF23 and αKlotho between NF1 patients and controls. No association was found between auxological, biochemical, genetic and radiological parameters and FGF23 values.

Conclusion

In conclusion, this represents the first study assessing FGF23 levels in NF1 children and its possible relationship with decreased bone mineral density. Contrarily to previous observations, no significant differences were found between NF1 patients and controls regarding FGF23 and αKlotho levels. Additionally, there was no clear association between FGF23 and bone involvement, thus suggesting that this phenomenon is not FGF23-driven or FGF23 derangements might occur later in life. Further research is needed to understand the multifactorial mechanisms and determine optimal intervention strategies.

Publication and source details

Original title: Neurofibromatosis type I (NF1) and bone involvement in a pediatric setting: insights from FGF23 levels

Giulia Rodari; Valeria Citterio; Masami Ikehata; Deborah Mattinzoli; Giulietta Scuvera; Federico Grilli; Eriselda Profka; Federico Giacchetti; Valentina Collini; Alessandro Risio; Claudia Cesaretti; Federica Natacci; Carlo Alfieri; Giovanna Mantovani; Claudia Giavoli

Italian Journal of Pediatrics · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T06:07:34.306217+00:00

DOI: 10.1186/s13052-025-01941-9 · PMC11934798